We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+17.63%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$808M
AUM Growth
+$311M
Cap. Flow
+$255M
Cap. Flow %
31.62%
Top 10 Hldgs %
37.23%
Holding
104
New
33
Increased
25
Reduced
12
Closed
31

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$46.9M
2
ZBH icon
Zimmer Biomet
ZBH
+$40.8M
3
MCK icon
McKesson
MCK
+$27.7M
4
THC icon
Tenet Healthcare
THC
+$16.5M
5
BSX icon
Boston Scientific
BSX
+$16.4M

Top Sells

Rank Stock Value
1
SYK icon
Stryker
SYK
+$14.3M
2
TFX icon
Teleflex
TFX
+$11.7M
3
CAH icon
Cardinal Health
CAH
+$11.5M
4
BIIB icon
Biogen
BIIB
+$11.1M
5
IDXX icon
Idexx Laboratories
IDXX
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 94.35%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DHR icon
26
Danaher
DHR
$147B
$12M 1.49%
+56,400
New +$11.9M
JNJ icon
27
Johnson & Johnson
JNJ
$631B
$11.9M 1.48%
+72,000
New +$11.6M
VKTX icon
28
Viking Therapeutics
VKTX
$4.02B
$11.8M 1.47%
730,000
+2,900
+0.4% +$60.8K
VTYX
29
DELISTED
Ventyx Biosciences
VTYX
$11.5M 1.42%
350,000
+60,000
+21% +$2.07M
SGRY icon
30
Surgery Partners
SGRY
$2.09B
$11.2M 1.39%
250,000
+128,000
+105% +$4.88M
NVS icon
31
Novartis
NVS
$298B
$10.4M 1.29%
+103,000
New +$10.3M
REPL icon
32
Replimune Group
REPL
$1.15B
$10.3M 1.28%
445,000
+50,000
+13% +$977K
PEN icon
33
Penumbra
PEN
$12.8B
$10.3M 1.28%
30,000
-5,000
-14% -$1.54M
ALNY icon
34
Alnylam Pharmaceuticals
ALNY
$29B
$9.88M 1.22%
52,000
+32,000
+160% +$6.34M
RVMD icon
35
Revolution Medicines
RVMD
$44.4B
$9.52M 1.18%
356,000
+11,000
+3% +$270K
NARI
36
DELISTED
Inari Medical, Inc. Common Stock
NARI
$9.01M 1.12%
155,000
+55,000
+55% +$3.47M
ITCI
37
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$8.99M 1.11%
+142,000
New +$8.85M
ALKS icon
38
Alkermes
ALKS
$8.29B
$8.89M 1.1%
284,000
+105,000
+59% +$3.18M
RLAY icon
39
Relay Therapeutics
RLAY
$4.37B
$8.79M 1.09%
700,000
-70,000
-9% -$871K
NTLA icon
40
Intellia Therapeutics
NTLA
$1.68B
$8.4M 1.04%
+206,000
New +$8.35M
EXAS
41
DELISTED
Exact Sciences
EXAS
$8.26M 1.02%
88,000
-74,000
-46% -$5.77M
TEVA icon
42
Teva Pharmaceuticals
TEVA
$42.1B
$7.53M 0.93%
+1,000,000
New +$8.11M
KRYS icon
43
Krystal Biotech
KRYS
$9.81B
$7.28M 0.9%
62,000
-23,000
-27% -$2.35M
PTCT icon
44
PTC Therapeutics
PTCT
$6.23B
$7.08M 0.88%
174,000
-4,000
-2% -$196K
LFST icon
45
Lifestance Health
LFST
$4.55B
$7.06M 0.87%
773,000
+64,000
+9% +$532K
MDT icon
46
Medtronic
MDT
$114B
$7.05M 0.87%
+80,000
New +$6.89M
APLS
47
DELISTED
Apellis Pharmaceuticals
APLS
$6.56M 0.81%
+72,000
New +$6.21M
RVNC
48
DELISTED
Revance Therapeutics, Inc.
RVNC
$6.33M 0.78%
250,000
– –
TGTX icon
49
TG Therapeutics
TGTX
$7.52B
$6.21M 0.77%
+250,000
New +$6.46M
SIBN icon
50
SI-BONE Inc
SIBN
$844M
$6.12M 0.76%
+227,000
New +$5.54M
1
2
3 4 5

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q2 2023 Portfolio in Review

As of Q2 2023, Integral Health Asset Management held 104 positions worth $808M, up 63% from $496M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Integral Health Asset Management deployed $255M of net new capital in Q2 2023, opening 33 new positions and adding to 25 existing holdings. Its largest new stake was Cigna: 180,000 shares worth $50.5M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Elevance Health, an estimated $9.69M trimmed.

  • Integral Health Asset Management's largest Q2 2023 buy was Cigna: 180,000 shares worth $50.5M.
  • Integral Health Asset Management added most to Boston Scientific in Q2 2023, an estimated $16.4M increase.
  • Integral Health Asset Management's biggest Q2 2023 reduction was Elevance Health, cutting an estimated $9.69M.
  • Integral Health Asset Management fully exited Stryker in Q2 2023, selling an estimated $14.3M.
  • Integral Health Asset Management's ten largest holdings make up 37% of its $808M portfolio in Q2 2023.
  • Integral Health Asset Management opened 33 new positions and closed 31 in Q2 2023.
  • Integral Health Asset Management's portfolio value rose 63% quarter-over-quarter to $808M.

Based on Integral Health Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.